Citations (81)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (11)
Valeria McCarroll. (2023) Mysticizing medicine: incorporating nondualism into the training of psychedelic guides. Interdisciplinary Science Reviews 48:5, pages 752-767.
Read now
Read now
Raman Sharma, Rachel Batchelor & Jacqueline Sin. (2023) Psychedelic Treatments for Substance Use Disorder and Substance Misuse: A Mixed Methods Systematic Review. Journal of Psychoactive Drugs 55:5, pages 612-630.
Read now
Read now
Stanley Wong, An Yi Yu, Nicholas Fabiano, Ofer Finkelstein, Aryan Pasricha, Brett D.M. Jones, Joshua D. Rosenblat, Daniel M. Blumberger, Benoit H. Mulsant & M. Ishrat Husain. (2023) Beyond Psilocybin: Reviewing the Therapeutic Potential of Other Serotonergic Psychedelics in Mental and Substance Use Disorders. Journal of Psychoactive Drugs 0:0, pages 1-17.
Read now
Read now
Debora Oliveira, Rodrigo Fontenele, Jeremy Weleff, Mehmet Sofuoglu & Joao P. De Aquino. (2023) Developing non-opioid therapeutics to alleviate pain among persons with opioid use disorder: a review of the human evidence. International Review of Psychiatry 35:5-6, pages 377-396.
Read now
Read now
Alexandra Arenson, Cynthia I. Campbell & Ilan Remler. (2023) Psychoactive plant derivatives (ayahuasca, ibogaine, kratom) and their application in opioid withdrawal and use disorder – a narrative review. Journal of Addictive Diseases 0:0, pages 1-11.
Read now
Read now
Jessica M. Brooks, Emre Umucu, Karen L. Fortuna, M. Carrington Reid, Kathlene Tracy & Lusine Poghosyan. (2022) Prevalence of lifetime nonmedical opioid use among U.S. Health Center Patients aged 45 years and older with psychiatric disorders. Aging & Mental Health 26:1, pages 179-185.
Read now
Read now
Matthias Luz & Deborah C. Mash. (2021) Evaluating the toxicity and therapeutic potential of ibogaine in the treatment of chronic opioid abuse. Expert Opinion on Drug Metabolism & Toxicology 17:9, pages 1019-1022.
Read now
Read now
Thomas K. Brown, Geoff E. Noller & Julie O. Denenberg. (2019) Ibogaine and Subjective Experience: Transformative States and Psychopharmacotherapy in the Treatment of Opioid Use Disorder. Journal of Psychoactive Drugs 51:2, pages 155-165.
Read now
Read now
Alan K. Davis, Elise Renn, Austin-Marley Windham-Herman, Martin Polanco & Joseph P. Barsuglia. (2018) A Mixed-Method Analysis of Persisting Effects Associated with Positive Outcomes Following Ibogaine Detoxification. Journal of Psychoactive Drugs 50:4, pages 287-297.
Read now
Read now
Benjamin J. Malcolm, Martin Polanco & Joseph P. Barsuglia. (2018) Changes in Withdrawal and Craving Scores in Participants Undergoing Opioid Detoxification Utilizing Ibogaine. Journal of Psychoactive Drugs 50:3, pages 256-265.
Read now
Read now
Deborah C. Mash. (2018) Breaking the cycle of opioid use disorder with Ibogaine. The American Journal of Drug and Alcohol Abuse 44:1, pages 1-3.
Read now
Read now
Articles from other publishers (70)
Lianne de Wit, Hester Hendriks, Jacqueline van Engelen, Harm Heusinkveld, Anne Kienhuis, Emiel Rorije, Marjolijn Woutersen, Margriet van der Zee & Suzanne Jeurissen. (2024) New Approach Methodologies (NAMs) for ad hoc human health risk assessment of food and non-food products - Proceedings of a workshop. Regulatory Toxicology and Pharmacology 149, pages 105615.
Crossref
Crossref
Samuel A. Bradley, Frederik G. Hansson, Beata J. Lehka, Daniela Rago, Pedro Pinho, Huadong Peng, Khem B. Adhikari, Ahmad K. Haidar, Lea G. Hansen, Daria Volkova, Maxence Holtz, Sergi Muyo Abad, Xin Ma, Konstantinos Koudounas, Sébastien Besseau, Nicolas Gautron, Céline Mélin, Jillian Marc, Caroline Birer Williams, Vincent Courdavault, Emil D. Jensen, Jay D. Keasling, Jie Zhang & Michael K. Jensen. (2024) Yeast Platforms for Production and Screening of Bioactive Derivatives of Rauwolscine. ACS Synthetic Biology.
Crossref
Crossref
Benjamin M. Williams, Nathan D. Steed, Joel T. Woolley, Aubrey A. Moedl, Christina A. Nelson, Gavin C. Jones, Matthew D. Burris, Hugo R. Arias, Oc-Hee Kim, Eun Young Jang, Arik J. Hone, J. Michael McIntosh, Jordan T. Yorgason & Scott C. Steffensen. (2024) Catharanthine Modulates Mesolimbic Dopamine Transmission and Nicotine Psychomotor Effects via Inhibition of α6-Nicotinic Receptors and Dopamine Transporters. ACS Chemical Neuroscience.
Crossref
Crossref
Agnieszka D. Sekula, Prashanth Puspanathan, Luke Downey & Paul Liknaitzky. (2024) Producing Altered States of Consciousness, Reducing Substance Misuse: A Review of Psychedelic-Assisted Psychotherapy, Transcendental Meditation and Hypnotherapy. Psychoactives 3:2, pages 137-162.
Crossref
Crossref
Thomas Knuijver, Rob ter Heine, Arnt F. A. Schellekens, Paniz Heydari, Luc Lucas, Sjoerd Westra, Maarten Belgers, Toon van Oosteren, Robbert Jan Verkes & Cornelis Kramers. (2024) The pharmacokinetics and pharmacodynamics of ibogaine in opioid use disorder patients. Journal of Psychopharmacology.
Crossref
Crossref
Juan Pedro Castro-Nin, Diego Serantes, Paola Rodriguez, Bruno Gonzalez, Ignacio Carrera, Pablo Torterolo & Joaquín González. (2024) Noribogaine acute administration in rats promotes wakefulness and suppresses REM sleep. Psychopharmacology.
Crossref
Crossref
Kirsten CherianKenneth Shinozuka, Burton J. TabaacAlejandro ArenasBryce D. BeutlerViviana D. EvansChelsey FasanoOwen S. Muir. (2024) Psychedelic Therapy: A Primer for Primary Care Clinicians—Ibogaine. American Journal of Therapeutics 31:2, pages e133-e140.
Crossref
Crossref
Kirsten N. Cherian, Jackob N. Keynan, Lauren Anker, Afik Faerman, Randi E. Brown, Ahmed Shamma, Or Keynan, John P. Coetzee, Jean-Marie Batail, Angela Phillips, Nicholas J. Bassano, Gregory L. Sahlem, Jose Inzunza, Trevor Millar, Jonathan Dickinson, C. E. Rolle, Jennifer Keller, Maheen Adamson, Ian H. Kratter & Nolan R. Williams. (2024) Magnesium–ibogaine therapy in veterans with traumatic brain injuries. Nature Medicine 30:2, pages 373-381.
Crossref
Crossref
Yu Kyung Lee, Mark S. Gold, Kenneth Blum, Panayotis K. Thanos, Colin Hanna & Brian S. Fuehrlein. (2024) Opioid use disorder: current trends and potential treatments. Frontiers in Public Health 11.
Crossref
Crossref
Judit Biosca-Brull, Genis Ona, Lineth Alarcón-Franco & Maria Teresa Colomina. (2024) A transcriptomic analysis in mice following a single dose of ibogaine identifies new potential therapeutic targets. Translational Psychiatry 14:1.
Crossref
Crossref
Genís Ona, Ingrid Reverte, Giordano N Rossi, Rafael G dos Santos, Jaime EC Hallak, Maria Teresa Colomina & José Carlos Bouso. (2023) Main targets of ibogaine and noribogaine associated with its putative anti-addictive effects: A mechanistic overview. Journal of Psychopharmacology 37:12, pages 1190-1200.
Crossref
Crossref
Samuel A. Bradley, Beata J. Lehka, Frederik G. Hansson, Khem B. Adhikari, Daniela Rago, Paulina Rubaszka, Ahmad K. Haidar, Ling Chen, Lea G. Hansen, Olga Gudich, Konstantina Giannakou, Bettina Lengger, Ryan T. Gill, Yoko Nakamura, Thomas Dugé de Bernonville, Konstantinos Koudounas, David Romero-Suarez, Ling Ding, Yijun Qiao, Thomas M. Frimurer, Anja A. Petersen, Sébastien Besseau, Sandeep Kumar, Nicolas Gautron, Celine Melin, Jillian Marc, Remi Jeanneau, Sarah E. O’Connor, Vincent Courdavault, Jay D. Keasling, Jie Zhang & Michael K. Jensen. (2023) Biosynthesis of natural and halogenated plant monoterpene indole alkaloids in yeast. Nature Chemical Biology 19:12, pages 1551-1560.
Crossref
Crossref
Alessio Mosca, Stefania Chiappini, Andrea Miuli, Gianluca Mancusi, Maria Chiara Santovito, Francesco Di Carlo, Mauro Pettorruso, John M. Corkery, Carlos Canessa, Giovanni Martinotti & Massimo Di Giannantonio. (2023) Ibogaine/Noribogaine in the Treatment of Substance Use Disorders: A
Systematic Review of the Current Literature. Current Neuropharmacology 21:11, pages 2178-2194.
Crossref
Crossref
Victor P. Acero, Emily S. Cribas, Kevin D. Browne, Olivia Rivellini, Justin C. Burrell, John C. O’Donnell, Suradip Das & D. Kacy Cullen. (2023) Bedside to bench: the outlook for psychedelic research. Frontiers in Pharmacology 14.
Crossref
Crossref
Nicolas Garel, Jessica Drury, Julien Thibault Lévesque, Nathalie Goyette, Alexandre Lehmann, Karl Looper, David Erritzoe, Shannon Dames, Gustavo Turecki, Soham Rej, Stephane Richard-Devantoy & Kyle T. Greenway. (2023) The Montreal model: an integrative biomedical-psychedelic approach to ketamine for severe treatment-resistant depression. Frontiers in Psychiatry 14.
Crossref
Crossref
Samane Jahanabadi, Shayan Amiri, Mehdi Karkeh-abadi & Ali Razmi. (2023) Natural psychedelics in the treatment of depression; a review focusing on neurotransmitters. Fitoterapia 169, pages 105620.
Crossref
Crossref
Mary G. Hornick & Ashley Stefanski. (2023) Hallucinogenic potential: a review of psychoplastogens for the treatment of opioid use disorder. Frontiers in Pharmacology 14.
Crossref
Crossref
Manzar Zare & Monnica T. Williams. (2023) Muslim Women and Psychedelics: a Look at the Past, Present, and Future. International Journal of Mental Health and Addiction.
Crossref
Crossref
Rabeet Tariq. (2023) Using Psychedelics in Clinical Practice: Comparing Therapeutic Uses and Potential Harms. Current Reviews in Clinical and Experimental Pharmacology 18:2, pages 94-109.
Crossref
Crossref
Bruno González, Nicolás Veiga, Gonzalo Hernández, Gustavo Seoane & Ignacio Carrera. (2023) Reactivity of the Iboga Skeleton: Oxidation Study of Ibogaine and Voacangine. Journal of Natural Products 86:6, pages 1500-1511.
Crossref
Crossref
Deborah C. Mash. (2023) IUPHAR – invited review - Ibogaine – A legacy within the current renaissance of psychedelic therapy. Pharmacological Research 190, pages 106620.
Crossref
Crossref
Jonathan Dickinson. (2023) Transpersonal Intersubjectivity in Ibogaine Experiences: Three cases. Anthropology of Consciousness 34:1, pages 161-180.
Crossref
Crossref
Borja J. Rodríguez‐Cano, Maja Kohek, Genís Ona, Miguel Ángel Alcázar‐Córcoles, Rafael G. dos Santos, Jaime E. C. Hallak & José Carlos Bouso. (2022) Underground ibogaine use for the treatment of substance use disorders: A qualitative analysis of subjective experiences. Drug and Alcohol Review 42:2, pages 401-414.
Crossref
Crossref
Andrea Mastinu, Margrate Anyanwu, Marinella Carone, Giulia Abate, Sara Anna Bonini, Gregorio Peron, Emanuela Tirelli, Mariachiara Pucci, Giovanni Ribaudo, Erika Oselladore, Marika Premoli, Alessandra Gianoncelli, Daniela Letizia Uberti & Maurizio Memo. (2023) The Bright Side of Psychedelics: Latest Advances and Challenges in Neuropharmacology. International Journal of Molecular Sciences 24:2, pages 1329.
Crossref
Crossref
C. Dauré & L. Mallet. 2023. Les Addictions. Les Addictions
593
599
.
Genaro Herrera Cano, Jordan Dean, Samuel Padilla Abreu, Amanda Hernández Rodríguez, Cyrena Abbasi, Madison Hinson & Brandon Lucke-Wold. (2022) Key Characteristics and Development of Psychoceuticals: A Review. International Journal of Molecular Sciences 23:24, pages 15777.
Crossref
Crossref
Jumi Hayaki, Haley Cinq-Mars, Paul P. Christopher, Bradley J. Anderson & Michael D. Stein. (2022) Opioid relapse and MOUD outcomes following civil commitment for opioid use. Journal of Substance Abuse Treatment 142, pages 108873.
Crossref
Crossref
Amber N. Edinoff, Natalie W. Wu, Catherine A. Nix, Bryce Bonin, Rama Mouhaffel, Stephen Vining, William Gibson, Elyse M. Cornett, Kevin S. Murnane, Adam M. Kaye & Alan D. Kaye. (2022) Historical Pathways for Opioid Addiction, Withdrawal with Traditional and Alternative Treatment Options with Ketamine, Cannabinoids, and Noribogaine: A Narrative Review. Health Psychology Research 10:4.
Crossref
Crossref
Ada Kałużna, Marco Schlosser, Emily Gulliksen Craste, Jack Stroud & James Cooke. (2022) Being no one, being One: The role of ego-dissolution and connectedness in the therapeutic effects of psychedelic experience. Journal of Psychedelic Studies 6:2, pages 111-136.
Crossref
Crossref
Brian S. Barnett & Jeremy Weleff. (2022) Psychedelics in the Treatment of Substance Use Disorders. Psychiatric Annals 52:9, pages 365-370.
Crossref
Crossref
Bruno Ramos Gomes & Luis Fernando Tofoli. (2022) A sacred plant of neuronal effect: the use of ibogaine in addiction treatments in Brazil. Anthropology of Consciousness 33:2, pages 333-357.
Crossref
Crossref
Bradford Martins, Will Rutland, Joao P. De Aquino, Benjamin L. Kazer, Melissa Funaro, Marc N. Potenza & Gustavo A. Angarita. (2022) Helpful or Harmful? The Therapeutic Potential of Medications with Varying Degrees of Abuse Liability in the Treatment of Substance Use Disorders. Current Addiction Reports 9:4, pages 647-659.
Crossref
Crossref
Patrick Köck, Katharina Froelich, Marc Walter, Undine Lang & Kenneth M. Dürsteler. (2022) A systematic literature review of clinical trials and therapeutic applications of ibogaine. Journal of Substance Abuse Treatment 138, pages 108717.
Crossref
Crossref
Genís Ona, Juliana Mendes Rocha, José Carlos Bouso, Jaime E. C. Hallak, Tre Borràs, Maria Teresa Colomina & Rafael G. dos Santos. (2021) The adverse events of ibogaine in humans: an updated systematic review of the literature (2015–2020). Psychopharmacology 239:6, pages 1977-1987.
Crossref
Crossref
Hugo R. Arias, Cecilia M. Borghese, Allison L. Germann, Spencer R. Pierce, Alessandro Bonardi, Alessio Nocentini, Paola Gratteri, Thanvi M. Thodati, Natalie J. Lim, R. Adron Harris & Gustav Akk. (2022) (+)-Catharanthine potentiates the GABAA receptor by binding to a transmembrane site at the β(+)/α(-) interface near the TM2-TM3 loop. Biochemical Pharmacology 199, pages 114993.
Crossref
Crossref
Margarida L. F. Martins, Paniz Heydari, Wenlong Li, Alejandra Martínez-Chávez, Nikkie Venekamp, Maria C. Lebre, Luc Lucas, Jos H. Beijnen & Alfred H. Schinkel. (2022) Drug Transporters ABCB1 (P-gp) and OATP, but not Drug-Metabolizing Enzyme CYP3A4, Affect the Pharmacokinetics of the Psychoactive Alkaloid Ibogaine and its Metabolites. Frontiers in Pharmacology 13.
Crossref
Crossref
Upkar Varshney, Neetu Singh, Anu G Bourgeois & Shanta R Dube. (2022) Review, Assess, Classify, and Evaluate (RACE): a framework for studying m-health apps and its application for opioid apps. Journal of the American Medical Informatics Association 29:3, pages 520-535.
Crossref
Crossref
Thomas Knuijver, Arnt Schellekens, Maarten Belgers, Rogier Donders, Toon van Oosteren, Kees Kramers & Robbert Verkes. (2021) Safety of ibogaine administration in detoxification of opioid‐dependent individuals: a descriptive open‐label observational study. Addiction 117:1, pages 118-128.
Crossref
Crossref
Yu Kyung Lee, Mark S. Gold & Brian S. Fuehrlein. (2022) Looking beyond the opioid receptor: A desperate need for new treatments for opioid use disorder. Journal of the Neurological Sciences 432, pages 120094.
Crossref
Crossref
Bruno González, Catherine Fagúndez, Alejandro Peixoto de Abreu Lima, Leopoldo Suescun, Diver Sellanes, Gustavo A. Seoane & Ignacio Carrera. (2021)
Efficient Access to the Iboga Skeleton: Optimized Procedure to Obtain Voacangine from
Voacanga africana
Root Bark
. ACS Omega 6:26, pages 16755-16762.
Crossref
Crossref
Jumi Hayaki, Micah T. Conti, Genie L. Bailey, Debra S. Herman, Bradley J. Anderson & Michael D. Stein. (2021) Negative affect-associated drug refusal self-efficacy, illicit opioid use, and medication use following short-term inpatient opioid withdrawal management. Journal of Substance Abuse Treatment 126, pages 108309.
Crossref
Crossref
Martie S. Underwood, Stephen J. Bright & B. Les Lancaster. (2021) A narrative review of the pharmacological, cultural and psychological literature on ibogaine. Journal of Psychedelic Studies 5:1, pages 44-54.
Crossref
Crossref
Joaquín González, Matias Cavelli, Santiago Castro-Zaballa, Alejandra Mondino, Adriano B. L. Tort, Nicolás Rubido, Ignacio Carrera & Pablo Torterolo. (2021) EEG Gamma Band Alterations and REM-like Traits Underpin the Acute Effect of the Atypical Psychedelic Ibogaine in the Rat. ACS Pharmacology & Translational Science 4:2, pages 517-525.
Crossref
Crossref
Shreyas Bhat, Daryl A. Guthrie, Ameya Kasture, Ali El-Kasaby, Jianjing Cao, Alessandro Bonifazi, Therese Ku, JoLynn B. Giancola, Thomas Hummel, Michael Freissmuth & Amy Hauck Newman. (2020) Tropane-Based Ibogaine Analog Rescues Folding-Deficient Serotonin and Dopamine Transporters. ACS Pharmacology & Translational Science 4:2, pages 503-516.
Crossref
Crossref
Kabir B. Nigam & Ananda K. Pandurangi. (2021) Do Hallucinogens Have a Role in the Treatment of Addictions? A Review of the Current Literature. SN Comprehensive Clinical Medicine 3:6, pages 1385-1395.
Crossref
Crossref
Monnica T. Williams, Sara Reed & Jamilah George. (2021) Culture and psychedelic psychotherapy: Ethnic and racial themes from three Black women therapists. Journal of Psychedelic Studies 4:3, pages 125-138.
Crossref
Crossref
Claire Wilson, Trevor Millar & Zak Matieschyn. (2021) Novel treatment of opioid use disorder using ibogaine and iboga in two adults. Journal of Psychedelic Studies 4:3, pages 149-155.
Crossref
Crossref
Michaela Barber, John Gardner, Michael Savic & Adrian Carter. (2020) Ibogaine therapy for addiction: Consumer views from online fora. International Journal of Drug Policy 83, pages 102857.
Crossref
Crossref
Joost J. Breeksema, Alistair R. Niemeijer, Erwin Krediet, Eric Vermetten & Robert A. Schoevers. (2020) Psychedelic Treatments for Psychiatric Disorders: A Systematic Review and Thematic Synthesis of Patient Experiences in Qualitative Studies. CNS Drugs 34:9, pages 925-946.
Crossref
Crossref
Hugo R. Arias, Jean Luc Do Rego, Jean Claude Do Rego, Zhenglan Chen, Youssef Anouar, Petra Scholze, Eric B. Gonzales, Renqi Huang & Abdeslam Chagraoui. (2020) Coronaridine congeners potentiate GABAA receptors and induce sedative activity in mice in a benzodiazepine-insensitive manner. Progress in Neuro-Psychopharmacology and Biological Psychiatry 101, pages 109930.
Crossref
Crossref
Paola Rodrı́guez, Jessika Urbanavicius, José Pedro Prieto, Sara Fabius, Ana Laura Reyes, Vaclav Havel, Dalibor Sames, Cecilia Scorza & Ignacio Carrera. (2020) A Single Administration of the Atypical Psychedelic Ibogaine or Its Metabolite Noribogaine Induces an Antidepressant-Like Effect in Rats. ACS Chemical Neuroscience 11:11, pages 1661-1672.
Crossref
Crossref
A Benjamin Srivastava, John J Mariani & Frances R Levin. (2020) New directions in the treatment of opioid withdrawal. The Lancet 395:10241, pages 1938-1948.
Crossref
Crossref
Dominique Denis-Lalonde & Andrew Estefan. (2020) Emerging Psychedelic-Assisted Therapies: Implications for Nursing Practice. Journal of Mental Health and Addiction Nursing 4:1, pages e1-e13.
Crossref
Crossref
Kelly E. Dunn, Andrew S. Huhn, Cecilia L. Bergeria, Cassandra D. Gipson & Elise M. Weerts. (2019) Non-Opioid Neurotransmitter Systems that Contribute to the Opioid Withdrawal Syndrome: A Review of Preclinical and Human Evidence. Journal of Pharmacology and Experimental Therapeutics 371:2, pages 422-452.
Crossref
Crossref
James Grogan, Roy Gerona, Jerry W. Snow & Louise Kao. (2019) Ibogaine Consumption With Seizure-Like Episodes, QTc-Prolongation, and Captured Cardiac Dysrhythmias. The Journal of Emergency Medicine 57:4, pages e99-e104.
Crossref
Crossref
Felix Krengel, Teresa de Jesús Olivera-Flores, Josefina Herrera-Santoyo & Ricardo Reyes-Chilpa. (2019) Strategies for the in vitro production of antiaddictive ibogan type alkaloids from Apocynaceae species. Plant Cell, Tissue and Organ Culture (PCTOC) 138:2, pages 215-227.
Crossref
Crossref
Soledad Marton, Bruno González, Sebastián Rodríguez-Bottero, Ernesto Miquel, Laura Martínez-Palma, Mariana Pazos, José Pedro Prieto, Paola Rodríguez, Dalibor Sames, Gustavo Seoane, Cecilia Scorza, Patricia Cassina & Ignacio Carrera. (2019) Ibogaine Administration Modifies GDNF and BDNF Expression in Brain Regions Involved in Mesocorticolimbic and Nigral Dopaminergic Circuits. Frontiers in Pharmacology 10.
Crossref
Crossref
KENNETH V. ISERSON. (2018) “Go Ask Alice”: The Case for Researching Schedule I Drugs. Cambridge Quarterly of Healthcare Ethics 28:1, pages 168-177.
Crossref
Crossref
Esther Blessing, Sanya Virani & John Rotrosen. 2020. Substance Use Disorders. Substance Use Disorders
167
202
.
Maarten E. A. Reith & Margaret E. Gnegy. 2020. Substance Use Disorders. Substance Use Disorders
265
297
.
Thomas Knuijver, Maarten Belgers, Wiebren Markus, Robbert-Jan Verkes, Toon van Oosteren & Arnt Schellekens. (2018) Hallucinogen Persisting Perception Disorder After Ibogaine Treatment for Opioid Dependence. Journal of Clinical Psychopharmacology 38:6, pages 646-648.
Crossref
Crossref
Michael J. Wasko, Paula A. Witt-Enderby & Christopher K. Surratt. (2018) DARK Classics in Chemical Neuroscience: Ibogaine. ACS Chemical Neuroscience 9:10, pages 2475-2483.
Crossref
Crossref
Eduardo Ekman Schenberg. (2018) Psychedelic-Assisted Psychotherapy: A Paradigm Shift in Psychiatric Research and Development. Frontiers in Pharmacology 9.
Crossref
Crossref
Deborah C. Mash, Linda Duque, Bryan Page & Kathleen Allen-Ferdinand. (2018) Ibogaine Detoxification Transitions Opioid and Cocaine Abusers Between Dependence and Abstinence: Clinical Observations and Treatment Outcomes. Frontiers in Pharmacology 9.
Crossref
Crossref
Thaddeus James Camlin, Donald Eulert, Arthur Thomas Horvath, Steven F. Bucky, Joseph P. Barsuglia & Martin Polanco. (2018) A phenomenological investigation into the lived experience of ibogaine and its potential to treat opioid use disorders. Journal of Psychedelic Studies 2:1, pages 24-35.
Crossref
Crossref
Joaquín González, José P. Prieto, Paola Rodríguez, Matías Cavelli, Luciana Benedetto, Alejandra Mondino, Mariana Pazos, Gustavo Seoane, Ignacio Carrera, Cecilia Scorza & Pablo Torterolo. (2018) Ibogaine Acute Administration in Rats Promotes Wakefulness, Long-Lasting REM Sleep Suppression, and a Distinctive Motor Profile. Frontiers in Pharmacology 9.
Crossref
Crossref
Christian Sueur. (2018) État des lieux de la recherche sur les capacités thérapeutiques des « substances hallucinogènes » au 21 e siècle. Psychotropes Vol. 23:3, pages 125-163.
Crossref
Crossref
John Martin Corkery. 2018. Psychedelic Neuroscience. Psychedelic Neuroscience
217
257
.
Joseph P. Barsuglia, Martin Polanco, Robert Palmer, Benjamin J. Malcolm, Benjamin Kelmendi & Tanya Calvey. 2018. Psychedelic Neuroscience. Psychedelic Neuroscience
121
158
.
Jordan Sloshower. 2018. Plant Medicines, Healing and Psychedelic Science. Plant Medicines, Healing and Psychedelic Science
113
132
.